Hims Reports $33M Loss Amid Shift to GLP-1 Weight Loss Drugs
Hims & Hers Health Inc. (Hims) incurred a $33 million non-cash impairment charge in Q2 2024 due to its strategic pivot toward GLP-1 weight loss medica...
Hims & Hers Health Inc. (Hims) incurred a $33 million non-cash impairment charge in Q2 2024 due to its strategic pivot toward GLP-1 weight loss medica...
Hims & Hers, a leading telehealth company, reported a sales miss as competition in the digital health space intensifies. The company's financial resul...
Robert F. Kennedy Jr.'s campaign to ease federal restrictions on peptides could trigger a massive wellness trend, benefiting telehealth firms, compoun...